港股生物医药公司华昊中天医药B股在2024年11月1日上市首日就出现大涨行情,盘中一度涨14.42%,引发市场广泛关注。
据了解,华昊中天医药成立于2002年,是一家专注于肿瘤创新药物研发的合成生物学技术驱动型生物医药公司。该公司的主要产品优替德隆注射液于2021年获得国家药监局批准上市,2022年被纳入国家医保目录,2023年3月正式执行医保谈判价格,虽然让该产品价格下降超过60%,但在医保的放量作用下,销量近年来仍有所提高。
分析人士认为,华昊中天医药上市首日的大涨与其在港股上市时采取的"套路回拨"和"下限定价"策略有关,通过控制发行数量和定价来推高首日股价。另外,公司主打产品纳入医保,利好未来销量增长,也成为推动股价上涨的利好因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.